Fig. 4: Cell pathway changes associated with transition to overt leukemia.
From: The Eμ-Ret mouse is a novel model of hyperdiploid B-cell acute lymphoblastic leukemia
A The most significantly enriched pathways (MeSH terms), either up-regulated or downregulated in leukemia cells compared to preleukemia, identified by GSEA (FDR < 0.05). B GSEA plots depicting gene enrichment in selected pathways. Adjusted p values for multiple testing are shown. C Preleukemic cells isolated from healthy 4-week-old Eμ-Ret mouse spleens (PL) or splenic leukemia cells (Leuk) from moribund Eμ-Ret mice were cultured in the presence or absence anti-IL-7R antibody and their fold expansion/depletion calculated as the number of viable cells at 72 h divided by the number seeded into culture (fold change of preleukemia (n = 9) vs. leukemic cells (n = 12), p = 0.012). D Splenic BCP cell burden in NSG recipients of preleukemic or leukemic cells, 14 days after treatment with anti-IL7Rα or control antibody. Left panel shows density plot for one representative NSG mouse from each group; right panel shows cell numbers recovered from each recipient NSG mouse from 4 independent preleukemia population samples and one representative leukemic cell sample. For Ig vs. αIL-7R, p < 0.0001 for preleukemia and p = 0.7 for leukemic cells (p values were calculated using student’s t-test; NS not significant).
